Format

Send to

Choose Destination
See comment in PubMed Commons below
Onco Targets Ther. 2012;5:91-102. doi: 10.2147/OTT.S25117. Epub 2012 May 21.

Targeted therapy for esophagogastric cancers: a review.

Author information

1
Flinders Medical Centre, Adelaide, South Australia.

Abstract

The incidence of esophagogastric cancers is increasing rapidly in the Western population. Despite better understanding of the biology and intense research in the treatment of these cancers, the long-term survival remains poor both in the locally advanced and metastatic settings. The addition of combined modality strategies has resulted in modest improvement in 5-year survival rates. A number of biologic agents targeting epidermal-derived growth factor receptor, vascular endothelial derived growth factor and its receptor, and mammalian target of rapamycin (mTOR) are being currently evaluated in Phase II and III clinical trials. Some of these, like trastuzumab, cetuximab, and bevacizumab, have shown promising results. This review provides a brief overview of the recent developments in biologic agents for the treatment of esophagogastric cancers.

KEYWORDS:

Her2-positive EGC; VEGF; adenocarcinoma; squamous cell carcinoma; trastuzumab

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center